Phase II Study of ABT-888 and Temozolomide in Patients With Advanced Hepatocellular Carcinoma (HCC) Progressing Following Sorafenib Treatment or Intolerant to Sorafenib
Phase of Trial: Phase II
Latest Information Update: 13 Apr 2017
At a glance
- Drugs Veliparib (Primary) ; Temozolomide
- Indications Liver cancer
- Focus Therapeutic Use
- 04 Feb 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 04 Feb 2014 Planned End Date changed from 1 Dec 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov record.
- 18 Jan 2014 Interim results presented at the 2014 Gastrointestinal Cancers Symposium.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History